TENX

Tenax Therapeutics, Inc.

Healthcare
Biotechnology
$49M market cap

Forecast run · Sep 14, 2026Upside rank 12 of 3,136

Model Signal

ForecastQ Daily Probabilities

90.5%

38.8%

62.6%

Analyst Consensus

Recommendation2.44/5 Buy

Last price$1.86

Price target$4.40

Implied move+136.6%

Analysts9

ForecastQ Portfolios

TENX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.